Hope for the future
In this article, we hear Colin's story and the reasons why he has hope for the future.
Search results
In this article, we hear Colin's story and the reasons why he has hope for the future.
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Pancake Day or Shrove Tuesday, which in 2025 falls on Tuesday 4 March, could be a great opportunity to fundraise for Retina UK, whilst having fun and eating lots of yummy pancakes!
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
The development of a new treatment is a lengthy process, from early investigation of ideas and principles in the lab, through testing in cell and animal models to the final stages of clinical trials in human patients. The good news is that progress is increasingly rapid.
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
Growth factors are substances that promote the health and function of cells and tissues in the body.
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.
New stem cell treatment gains approval to enter US clinical trials